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Ten percent of the male (N=8 of 83) and1~%1bfth'e female (N = IS of 80) schizophrenic patientsmet'the criteria for the drug-free, good olltcome:group;: At admission, these 23 patients wcre comparable to the remaining schizophrenic cohort in agc, marital status, and family socioeconomic condition. The mean±SD age for all subjects was 28 ± 8.1 years, 25%· (N=40) were married, and most were upper-middle class (mean ±SO level = 1.6 ±0.93; Hollingshead-Redlich). fathers of the drug-frec patients with good outcomes, however, had attained a significantly higher level of education than fathers of the remaining patients (mean±SD level = 1.6±.77 versus 2.4±1.6; Hollingshead·Redlich; t=2.R, df=.H, p<.009). Significant differences in premorbid functioning are summarized in tahle I. Before the onset of illness, drug-free patients with good outcomes demonstrated beller functioning across a range of measures including social relations in latency, heterosexual relations, quality and stability of premorbid work functioning, and accrued psychosocial competence as reflected by acquisition of skills and interests.
Among the schizophrenic patients studied, comparison groups did not differ in age at onset (mean±SD= 19..3 ± 7.2 years), age at first hospitalization (23.3±6.5 years), months of prior outpatient treatment (17± HA), or numher of previous hospitalizations (3.1 ± l.2). By index admissioll, patients in both groups were (19) .
Outcome data were collected an average of 15 years after discharge (range=2-32 years) through interviews , with subjects and/or significant others by a member of '... the research team who was blind to the patient's baseline data. The information gathered was sufficient .to rate multidimensional and global outcome widl adequate reliability (20).
Minimal criteria for assigning follow-up patiellls to the drug-free, good outcome group included I) clinical ; global outcome score of moderate or better, 2) nevcr rehospitalized, and J) no psychotropic medication IISC during the follow-up period. Twenty-three (14%) of 163 patients with an index diagnosis of schizophrenia met thesc criteria. Overall, drug-frec patients with good outCOllll'S proved to be excellent informants and were among the highest functioning individuals in the study. They were employed for 80% of the follow-up period, and 70'X, (N= 16) were married. Sixty-three percent (12 of 19) had attended college after discharge and J I ':to (six of 19) had obtaincd a degree. They spent an average of 2 years in psychosocially oriented outpatient treatmellt without the usc of medications after index discharge. In most instances this treatment consisted of individual therapy with the psychiatrists who had treated them as inpatients. After this, most patients eschewed (111)' further psychiatric assistance; at follow-up only IVYo (N = 3) of these patients were currently in treatlllclll, compared to 74% (N= 104) of the remaining schiw· phrenic patients.
Potential predictors resided ill a set of baselll1c variables traversing sociodemographic and family characteristics, historical items, premorbid funclioning, and features of manifest illness (19, 20) . Disnilll· inating characteristics were identified by comparing drug-free patients with good Olllcomes to all other schizophrenic patients across these baseline diml'n· sions by using chi·square analysis for categorical var· iables and t tests for continuous variables. The prl·dic· tive power of a set of disninllnating charactcflSlIcS was then evaluated by using multiple regression and discriminant function al1:llyses. The patients we studied were treated and discharged during an era when institutional ideology discouraged the usc of medication. Most drug-free patients with good outcomes (78%, N=18) were not taking neUrDleptics at the time of admission, and those who were had phenothiazines discontinued during their hospitalization. By today's standards, far fewer patients would likely be drug free. Nevertheless, the data presented here demonstrate that over a prolonged postdischargc period, a definite proportion of DSM-lII schizophrenic patients sustained good outcome without medication. Furthermore, since drug-free patients with good outcomes did not need and/or were prone to avoid further psychiatric treatment, clinicians and researchers ma), have unJercstimated their numbers.
.' . Studied rctrospectively, our patients were distino guisheJ by certain demographic, premorbiJ, and c1i2
The nllmber of patients at each prognostic level is as follows: score of 3 or less, one good outcome patient with no medication and 11 poor outcome patients with medication; score of 4-6, three and 23 patients, respectively; score of 7-9. 11 and 10 patients. respec· tively; and score of 10-12, eight patients and one patient, respectively.
vals. Shown for comparison is the proportion of schizophrenic patients at each prognostic interval who demonstrated poor outcome (global scores of 0 or 1) in spite of continuous maintenance neuroleptic treatment over the entire follow-up period. Fony percent of the patients with the best prognosis sustained remission over the long term without medications. This proportion decreased progressively down the prognostic lad· der. Oq the other hand, the fact that few good prognosis but many poor prognosis patients did poorly while using medication may help explain contradictory findings from prospective studies with prognostically mixed patient samples.
.severely and chronically ill, although drug-free patients :cdwith' good outcomes had spent a significantly shorter :~;~?~perioq of time hospitalized (l0.9± 11.7 versus 29.8 ± :;;·;?;38.4·months; t=4.62, df=114, p<.OOOl).
,;~Xl~. .~·.At,. admission, drug-free patients with good out-.;--';'comes were more likely to manifest depressed mood~d ,)(48% ". )J.J~i·~:.prognosticscale for ch~onic schizo~hrenia was ;;~:i.~~~nstruaed that conceptualizes prognosIs as a dy-·:·~::.t~~amic. interplay between an individual's highest level Jt.i~f . .~daptive Qccupational and social functioning and ··;~:···~}thcJ!.~invasiveness" of his or hcr axis I disorder as ",' ····cstimated by family history of schizophrenia, preser-.vation of affect in psychopathology (depressed mood), and erosion of reality testing (psychotic assaultiveness) (10, 22) . Scores ranged from 12 (cxcellent premorbid social and work functioning, affect prescrved, and absence -of family history and assauhiveness) to 0 (poor premorbid social and work hllKlinning, absence of affect, positive family history, anJ assaultiveness). Figure 1 shows the proponion uf drug-free patients with good outcomes in each of fuur prognuslic inter-
• .'ial features that, by and largc, encompassed dassil: ·'fftdictors of outcome in schizophrenia_ Duration of ilncss per se was not predictive, however, since this '1I2S largely a chronic sample. Rather. what appeared rtant was the extent to which, at any time before hComing ill, the patient had acquired skills allowing ')an or her to embark on a mcaningful life path.
;;: Having found variables correlated with sustained .' ission without medication, we must urge caution in 'bing prospective predictive power to them. Mulriate analyses suggested that drug-free patiellls '.~th good outcomes derived from the group of pa-·;:'timts with good prognostic signs but underscored our Smited ability to predict specifically which of these i~d prognosis patients would do well without medi\f:atton. It appears that only a subgroup of good :~. prognosis patients, currently unidentifiable, can sus-:;: ain remission without medication. Taken with thẽ 7:observation that many poor prognosis patients remain r continuously disablcd despite medication, this hypoth-;{iais may explain conflicting reports in the literature.
't Patients who have done well without medication, ·twhen identified and characterized retrospective/)', ap-:\ pear as good prognosis patients (12) (13) (14) . Poor prog-';, nosis patients, as a group, tend to relapse with or -:: without medication (23). Therefore, when a prognosti-;~. ally mixed group of schizophrenic patients arc fol-:., lowed prospectively in a drug/placebo trial, the good prognosis patients will be found to benefit most from prophylactic medication (18). Thus, we reach the apparent contradiction that good prognosis schizophrenic patients are nor only most likely to respond to neuroleptic medications but arc also most likely to do well without them. A second source of inconsistencies across studies is the likelihood that a large portion of outcome variance is explained by characteristics of the social environment to which the patient returns (24) . Future swdics :assessing both patient and environmcntal prognostic characteristics such as expressed emotion will likely provide the most powerful discriminativc models.
Currently we have no established guidelines for identifying which paticnts have a low risk of relapse without pharmacotherapy; the decision to attempt a trail off of medication remains largely based on clinical ,-judgment. Data presented here and elsewhere, however, suggest that relative risk may best be assessed by the extent to which the skills and capacities of the patient measure up against rhe complexity and demands of his or her living situation.
